Assembly Biosciences Inc $ 14.12 0.04 (0.28%)
Volume:
677,687
Avg Vol (1m):
465,925
Market Cap $:
363.05 Mil
Enterprise Value $:
202.14 Mil
P/E (TTM):
0.00
P/B:
2.13
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $14.12 | ||
Manual of Stocks™ Web
Financial Strength | 5.8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 13.49 | ||
| Equity-to-Asset | 0.72 | ||
| Debt-to-Equity | 0.07 | ||
| Debt-to-EBITDA | -0.13 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | -0.62 | ||
| Beneish M-Score | -1.62 | ||
| WACC vs ROIC | |||
Profitability | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -646.82 | ||
| Net Margin % | -622.25 | ||
| ROE % | -52.14 | ||
| ROA % | -39.04 | ||
| ROC (Joel Greenblatt) % | -1534.96 | ||
| 3-Year EBITDA Growth Rate | -28.9 | ||
| 3-Year EPS without NRI Growth Rate | -30 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 2.13 | ||
| PS Ratio | 23.99 | ||
| EV-to-EBIT | -2.1 | ||
| EV-to-EBITDA | -2.1 | ||
| EV-to-Revenue | 13.47 | ||
| Current Ratio | 9.2 | ||
| Quick Ratio | 9.2 | ||
| Days Sales Outstanding | 70.71 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.8 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.73 | ||
| Price-to-Median-PS-Value | 0.38 | ||
| Earnings Yield (Greenblatt) % | -47.98 |